Collagen cross-linking is a treatment for multiple ophthalmic disorders. In some cases, collagen cross-linking may also be combined with other treatments to improve corneal strength or optical refraction, such as corneal ring segment inserts, topography-guided laser, and the like. Corrective lenses are normally required after these treatments for weakened corneas, but with smaller, more normalized prescriptions. Increased corneal symmetry allows for more comfortable contact lens wear, often of daily disposable lenses. Collagen cross-linking limits deterioration of vision, increases unaided and uncorrected vision, and may reduce the need for corneal transplantation. Collagen cross-linking may also have a role in stabilizing and “locking in” refractive effects of other procedures.
Disclosed herein, in certain embodiments, is a method of applying an ophthalmic composition to an eye, comprising applying the ophthalmic composition after preparing the epithelium of an eye for more effective treatment. In some embodiments, the method comprises preparing the epithelium of the eye by rubbing or contacting the eye with a first sponge device, so as to manipulate or “buff” the tissue of the epithelium. In some embodiments, the method comprises preparing the epithelium of the eye by rubbing the eye with the first sponge device in a circular pattern. In some embodiments, the method comprises removing lipids, mucus and microvilli. In some embodiments, the first sponge device comprises a handle with a sponge attached to one end of the handle for contacting the eye. In some embodiments, the sponge is dry or pre-wetted with an ophthalmic composition. In some embodiments, the sponge is pre-wetted with a riboflavin composition, artificial tears, or a combination thereof. In some embodiments, use of the first sponge device to prepare the epithelium markedly increases the permeability of the epithelium to medications or ophthalmic solutions applied to the surface of the epithelium after preparation or polishing with the buffing or polishing sponge.
In some embodiments, the method further comprises applying the ophthalmic composition with a second, loading sponge or sponge device. In some embodiments, the method further comprises placing the second sponge or sponge device over the eye to act as a depot or reservoir for holding the ophthalmic composition or solution in contact with the eye surface over an area where the solution needs to be absorbed into the eye.
In certain embodiments, the second sponge device comprises a round, loading sponge which peri- or pre-operatively covers all or a portion of the eye surface. In some embodiments, the size of the loading sponge does not exceed the eye surface. In some embodiments, the diameter of the sponge is about 3 mm. to about 12 mm. In some embodiments, the second sponge device has a diameter of around 11.5 mm and may be pre-formed to follow the curvature of most or all of the exposed, curved surface of the eye or may be of flexible material designed to adopt the shape of the exposed, curved surface of the eye. In some embodiments, the second sponge device or loading sponge may be pre-saturated with an ophthalmic solution. In some embodiments, the second sponge device may be placed on the eye surface and solution can be dripped onto the sponge device after placement. In some embodiments, the ophthalmic solution may comprise 0.2% to 10.0% by weight riboflavin in an aqueous carrier, and optionally, sodium iodide, catalase, artificial tears, or any combinations thereof.
Disclosed herein, in certain embodiments, is a first or preparation sponge device for use in manipulation of tissue on the surface of an eye prior to application of the second sponge device or loading sponge. The first, preparation sponge device comprises a preparation sponge having a tissue preparation surface shaped for manipulating and rubbing across the surface of an eye. In some embodiments, the preparation sponge has little or no risk of disrupting or perforating the epithelium. In some embodiments, the first sponge device further comprises a handle operatively connected to the preparation sponge. In some embodiments, the first sponge device may be a spherical or part spherical sponge without a handle, and may be held by forceps or similar instruments during preparation of the eye surface. In some embodiments, at least the tissue preparation surface of the sponge is round or at least partially round. In some embodiments, at least the tissue preparation surface of the sponge does not have sharp edges. In some embodiments, the tissue preparation surface of the sponge is rounded. In some embodiments the sponge of the first sponge device is of part circular shape. In some embodiments, the sponge may have a straight edge or other shaped edge attached to the handle. In some embodiments, the preparation sponge is made of a cellulose sponge material. In some embodiments, the preparation sponge is made of polyvinyl acetate (PVA) sponge material. In some embodiments, the preparation sponge is wetted with an ophthalmic solution prior to use in preparation of the eye surface. In some embodiments, the ophthalmic solution is 0.2% to 10.0% by weight riboflavin in an aqueous carrier, and optionally, sodium iodide, catalase, artificial tears, or any combinations thereof.
Use of the first, preparation sponge device followed by the second sponge device or loading sponge may augment or enhance delivery of any ophthalmic treatment solution to the eye for use in photochemical treatment of the cornea or for other types of treatment, such as application of eye medications such as glaucoma medications or anti-inflammatory medications such as steroids. In certain embodiments, the treatment solution is a riboflavin solution.
Disclosed herein, in certain embodiments, are sponges that improve the passage or penetration of riboflavin or other ophthalmic drugs through the epithelial barrier to avoid the surgical complications that arise from de-epithelialization, which can result in more disruption of the tissue than is necessary for the procedure to be effective. The reduction in patient discomfort combined with more rapid restoration of visual acuity make a trans-epithelial procedure better for the patient. In some embodiments, the first and second sponge devices are sterile. In some embodiments, the preparation sponge is part circular shape when dry and is configured to absorb liquid and expand into a spherical or part-spherical shape when wetted. In some embodiments, the preparation sponge is spherical or part-spherical in its dry condition. The preparation sponge may be of cellulose, PVA, or urethane sponge material. The first sponge device or preparation sponge has little or no risk of disrupting or perforating the epithelium, resulting in as little disruption of the epithelium as possible while still increasing penetration of the riboflavin or other solution into the deeper layers of the cornea without disrupting or causing any significant epithelial defects in the corneal surface.
In some embodiments, the first or preparation sponge device is of sponge or other sponge-like materials designed to enhance epithelial permeability by gently removing lipids, mucus, and dead surface epithelial cells. In some embodiments, the preparation sponge is packaged along with a blunt plastic shaft or other tool to assist in “twirling” this sponge around on the cornea or sclera or other parts of the eye to manipulate the tissue to be treated in an effort to enhance penetration of the riboflavin or other solution into the eye.
Further disclosed herein, in certain embodiments, is a method of using a first sponge device or preparation sponge as disclosed herein to improve the penetration of riboflavin or other ophthalmic drugs through the epithelial barrier to avoid the surgical complications that arise from de-epithelialization, which in some embodiments result in more disruption of the tissue than is necessary for the procedure to be effective. The reduction in patient discomfort combined with more rapid restoration of visual acuity make a trans-epithelial procedure better for the patient. In some embodiments, the preparation sponge is rubbed gently over the surface of the eye in a circular pattern after application of a topical anesthetic, in order to prepare the epithelium for improved penetration of riboflavin or other solutions. In some embodiments, the method removes lipids, mucus, microvilli and other natural barriers to riboflavin or other ocular solutions loading into the deeper ocular tissues. In some embodiments, it is possible that this preparation may produce very fine micro-abrasion to allow the riboflavin solution to penetrate through the epithelium into the cornea more easily, but this is not essential and may not occur in all cases. In some embodiments, the method has little or no risk of disrupting or perforating the epithelium resulting in as little disruption of the epithelium as possible while still increasing penetration of the riboflavin or other solution into the deeper layers of the cornea. In some embodiments, the method further comprises applying an ophthalmic solution (e.g., a riboflavin solution) to the eye in any suitable manner. In some embodiments, the ophthalmic solution is applied through a second, loading sponge placed over the eye to act as a depot or reservoir for the ophthalmic solution, since the tear film itself is only about 5 microns thick, which offers only a very small reservoir of riboflavin solution. This also moisturizes the corneal surface.
In various embodiments, the sponge device is used in one or more microsurgical ophthalmic procedures for tissue manipulation and management of fluids. In other embodiments, the sponge device is used in one or more microsurgical ophthalmic procedures for the management of one or more fluids. In some embodiments, the sponge device is placed on the cornea to moisten the cornea during one or more microsurgical procedures.
The above devices and methods may be used in various microsurgical ophthalmic procedures, including preparation of the epithelium for loading of one or more fluids through the epithelium into the eye for photochemical or other treatment.
Other features and advantages of the present disclosure will become more readily apparent to those of ordinary skill in the art after reviewing the following detailed description and accompanying drawings.
The details of the present disclosure, both as to its structure and operation, may be gleaned in part by study of the accompanying drawings, in which like reference numerals refer to like parts, and in which:
Certain embodiments as disclosed herein provide for ocular treatment solution delivery devices and delivery augmentation methods. For example, according to embodiments of the disclosure, devices and methods are provided for preparing the corneal epithelium for better penetration of riboflavin solutions or other ophthalmic solutions into the cornea.
A popular treatment of corneal diseases, including keratoconus, post-LASIK ectasia, and pellucid marginal degeneration, involves the removal of the epithelium followed by administration of a riboflavin solution and irradiation by ultraviolet-A light. Riboflavin acts as a photosensitizer and facilitates the cross-linking of stromal collagen fiber which prevents further disease progression. However, the removal of the epithelium carries numerous risks for the patient, including post-operative pain, infection risk, delayed wound healing, corneal perforation, stromal haze, and herpetic keratitis. Therefore, it would be safer to treat the patient without having to surgically remove the epithelium. Unfortunately, there are many obstacles to this approach because the intact epithelium prevents the cornea from rapidly and conveniently absorbing the riboflavin solution. This invention discloses novel devices and methods for allowing convenient treatment of corneal diseases with medications or with ophthalmic solutions such as riboflavin solutions without removing the epithelium, and may increase the effectiveness of such treatments.
After reading this description it will become apparent to one skilled in the art how to implement the disclosure in various alternative embodiments and alternative applications. However, although various embodiments of the present disclosure will be described herein, it is understood that these embodiments are presented by way of example only, and not limiting. As such, this detailed description of various alternative embodiments should not be construed to limit the scope or breadth of the present disclosure as set forth in the appended claims.
The time period for sufficient riboflavin to penetrate into the cornea when the solution is applied in drops to the eye without removal or treatment of the epithelium layer can be one to three hours. This is a problem for both patients undergoing treatment and for surgeons, in view of the extended time period needed. In some embodiments described below, eye surface preparation or manipulation reduces the initial time needed for an ophthalmic solution (e.g., a riboflavin solution or other ophthalmic solution) to penetrate sufficiently into the cornea in as little as seven to eleven minutes without requiring removal of the epithelium, significantly reducing patient discomfort and the time needed to complete the treatment.
Manipulation of the epithelium prepares it for improved penetration of the epithelium by the ophthalmic solution (e.g., a riboflavin solution), without having to remove the epithelium altogether. The cornea absorbs the riboflavin well until the corneal stroma is sufficiently loaded.
In some embodiments, a first or preparation sponge device 20 as illustrated in
Sponge 24 has a rounded edge or rim 25 and a straight edge or rim 27, and is held at the center of the straight edge in recess 28 between spaced claws or end portions 29 of the shaft 21, as illustrated in
In some embodiments, the sponge 24 is pre-wetted prior to use so that it is in the expanded condition of
In some embodiments, rubbing or buffing the epithelium gently with the expanded sponge 24 removes lipids, mucus and microvilli as well as dead epithelial cells which would otherwise resist penetration of fluid through the epithelium. In some embodiments, the wet sponge is rubbed gently over the surface of the eye, for example in a circular pattern. In some embodiments, a topical anesthetic is applied to the eye before the application and use of the wet sponge.
Any suitable sponge shape or material is contemplated for use with the methods disclosed herein, including the sponge head shape of the first embodiment (
After completion of the polishing or buffing step, an ophthalmic solution is applied to the eye in any suitable manner. In some embodiments, the ophthalmic solution is applied through a second sponge device which comprises a solution holding or loading/moistening sponge 24 placed over the eye 26 as illustrated in
In some embodiments, the ophthalmic solution is dripped onto the holding or loading sponge while it is placed over the eye, or the sponge is pre-soaked with the ophthalmic solution, or both. The second, loading sponge, for example sponge 40 or 80, acts as a reservoir to hold the solution against the eye surface and to allow application of additional solution. Simply dropping ophthalmic solution directly onto the eye surface or placing drops onto the eye results in the drops running off the eye, and has a limited effect. In contrast, the solution holding sponge of this embodiment places ophthalmic solution directly against the surface of the eye in a location where treatment is needed over an extended time period, allowing more efficient penetration into the cornea. In some embodiments, the ophthalmic solution is a riboflavin solution of 0.2% to 10.0% by weight riboflavin in an aqueous carrier, and optionally, sodium iodide, catalase, artificial tear solution or any combination thereof. If the sponge is pre-loaded with riboflavin, it is stored in a dark packaging material prior to use to avoid or reduce light degradation. In some embodiments, the riboflavin solution contains other additives for increased cross-linking, for example additives as described in PCT Application Publication No. WO 2013/148896. In some embodiments, the sponge is round, but the sponge may be of other shapes (such as oval or eye shaped) in alternative embodiments. In some embodiments, the solution holding or loading sponge operatively covers all or a portion of the eye or the cornea. In some embodiments, the holding sponge is made from any suitable sponge material such as cellulose or any fast wicking, lint-free material such as polyvinyl acetate, for example any of the materials described above in connection with the manipulation or preparation sponge devices of
Where the sponge is a round sponge, the sponge operatively covers all or a portion of the eye or the cornea. In some embodiments, the size of the sponge does not exceed the size of the eye or the cornea. In some embodiments, the diameter of the sponge is about 3 mm to about 12 mm. In some embodiments, the sponge is about 1 mm to about 5 mm in thickness. A series of different diameter loading sponges may be provided for selection by the physician depending on the desired treatment area.
The above sponges may be used in the two stage method described above for enhanced, faster penetration of any ocular treatment solution through the epithelium and into the cornea, while reducing or minimizing the risk of epithelial defects. The ophthalmic solution may be an ocular riboflavin solution for use in corneal treatment such as photochemical cross linking, or for other ophthalmic uses. In one embodiment, the method may be used for application of a riboflavin solution which contains 0.1 wt. % to 5.0 wt. % riboflavin in an aqueous carrier solution, or up to 10.0% in some cases. In some embodiments, the solution contains about 0.5 wt. % riboflavin. In other examples, the solution contains about 1.0 wt. % riboflavin or about 2.0 wt. % riboflavin. The higher concentration of riboflavin can increase corneal cross-linking if associated with higher amounts of oxygen in the cornea. The riboflavin solution may be stored in an actinic glass or UV and visible light protected plastic containers prior to use, to avoid activation of the riboflavin by ambient light.
The above devices and methods are designed to increase permeability of the epithelium layer with low or minimal epithelial defects resulting from the preparation or tissue manipulation step. Results of testing show that use of the sponge of
Two formulations of riboflavin solution were tested to determine saturation or riboflavin solution loading time after pre-treatment of the epithelium using the preparation sponge devices of the above embodiments. Formulation 1 had a riboflavin concentration of 0.1%. Formulation 2 had a riboflavin concentration of 0.5%. Results are compared in
Saturation was determined using “serial slit-lamp assessments” of the cornea at approximately 5 minute intervals. Riboflavin has a characteristic green color when illuminated with visible light. Slit-lamp assessments using visible light reveal the depth and uniformity of riboflavin throughout the corneal thickness.
Inclusion Criteria:
Patients who had undergone trans-epithelial cross-linking in one or both eyes were included in the analysis. Patients with a diagnosis of keratoconus or post-LASIK ectasia were included in this analysis.
Exclusion Criteria:
Patients with previous RK, INTACS, more than one cross-linking procedure per eye, and/or patients who were pseudo-phakic or had a diagnosis of nuclear sclerotic cataract were excluded from this analysis
Results—Formulation 1, 0.1% Riboflavin, Formulation 2, 0.5% Riboflavin
The results are shown in
The time period for good, homogeneous loading of riboflavin solution into the cornea, i.e. trans epithelial riboflavin loading time, was about 10 to 30 minutes using the delivery augmentation and delivery methods described above. Corresponding loading times without removal or pre-treatment of the epithelium can be up to three hours, significantly adding to the overall time for completion of a corneal treatment procedure.
The above description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles described herein can be applied to other embodiments without departing from the spirit or scope of the invention. Thus, it is to be understood that the description and drawings presented herein present exemplary embodiments of the invention and are therefore representative of the subject matter which is broadly contemplated by the present invention. It is further understood that the scope of the present invention fully encompasses other embodiments that may become obvious to those skilled in the art and that the scope of the present invention is accordingly limited by nothing other than the appended claims.
This application is a continuation application of U.S. application Ser. No. 14/275,192, filed May 12, 2014, which is a continuation-in-part of International Application PCT/US2013/034187, filed Mar. 27, 2013, which claims priority to U.S. Provisional Application No. 61/617,339, filed Mar. 29, 2012, all of which are incorporated by reference herein in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3132068 | Behrman | May 1964 | A |
4098728 | Rosenblatt | Jul 1978 | A |
4676790 | Kern | Jun 1987 | A |
4863627 | Davies et al. | Sep 1989 | A |
5368590 | Itoh | Nov 1994 | A |
5433714 | Bloomberg | Jul 1995 | A |
5639481 | Kessler et al. | Jun 1997 | A |
5824073 | Peyman | Oct 1998 | A |
5843060 | Cercone | Dec 1998 | A |
5849291 | Kessler | Dec 1998 | A |
5954682 | Petrus | Sep 1999 | A |
6043237 | Meadows et al. | Mar 2000 | A |
6053936 | Koyama et al. | Apr 2000 | A |
6099521 | Shadduck | Aug 2000 | A |
6161544 | Devore et al. | Dec 2000 | A |
6162210 | Shadduck | Dec 2000 | A |
6183086 | Neubert | Feb 2001 | B1 |
6192888 | Chandler et al. | Feb 2001 | B1 |
D439655 | Chandler | Mar 2001 | S |
6248335 | Duan et al. | Jun 2001 | B1 |
6309656 | Pugliese et al. | Oct 2001 | B1 |
6413268 | Hartman | Jul 2002 | B1 |
6447537 | Hartman | Sep 2002 | B1 |
D464429 | Martin et al. | Oct 2002 | S |
6471691 | Kobayashi et al. | Oct 2002 | B1 |
6544165 | McNew | Apr 2003 | B1 |
6544286 | Perez | Apr 2003 | B1 |
6783539 | Timberlake et al. | Aug 2004 | B1 |
6880558 | Perez | Apr 2005 | B2 |
6905641 | Platt et al. | Jun 2005 | B2 |
7015252 | Fujii et al. | Mar 2006 | B2 |
7044945 | Sand | May 2006 | B2 |
7073510 | Redmond et al. | Jul 2006 | B2 |
7077839 | Hamblin et al. | Jul 2006 | B2 |
7097629 | Blair | Aug 2006 | B2 |
7186417 | Siegel et al. | Mar 2007 | B1 |
7220278 | Peyman | May 2007 | B2 |
7288106 | Heacock et al. | Oct 2007 | B2 |
7320786 | Chen | Jan 2008 | B2 |
7331350 | Kochevar et al. | Feb 2008 | B2 |
7479136 | Dotson | Jan 2009 | B2 |
7498156 | Goodrich et al. | Mar 2009 | B2 |
7727544 | Schwartz et al. | Jun 2010 | B2 |
7744590 | Eells et al. | Jun 2010 | B2 |
7753943 | Strong | Jul 2010 | B2 |
7892268 | Heacock et al. | Feb 2011 | B2 |
7943590 | Flugelman | May 2011 | B2 |
8034373 | Reynolds et al. | Oct 2011 | B2 |
8071135 | Liu et al. | Dec 2011 | B2 |
8092490 | Redmond et al. | Jan 2012 | B2 |
8100530 | Zhou et al. | Jan 2012 | B2 |
8106038 | Margaron et al. | Jan 2012 | B2 |
8177778 | Muller et al. | May 2012 | B2 |
8202272 | Muller et al. | Jun 2012 | B2 |
8215314 | Chan et al. | Jul 2012 | B2 |
8238993 | Maynard et al. | Aug 2012 | B2 |
8282629 | Mrochen et al. | Oct 2012 | B2 |
8348935 | Muller et al. | Jan 2013 | B2 |
8366689 | Marshall et al. | Feb 2013 | B2 |
8398628 | Muller | Mar 2013 | B2 |
8409189 | Muller | Apr 2013 | B2 |
8414911 | Mattson et al. | Apr 2013 | B2 |
8460278 | Muller | Jun 2013 | B2 |
8466203 | Paik et al. | Jun 2013 | B2 |
8469952 | Muller et al. | Jun 2013 | B2 |
8475437 | Mrochen et al. | Jul 2013 | B2 |
8545487 | Muller et al. | Oct 2013 | B2 |
8574277 | Muller et al. | Nov 2013 | B2 |
8580789 | Krueger et al. | Nov 2013 | B2 |
8652131 | Muller et al. | Feb 2014 | B2 |
8712536 | Muller et al. | Apr 2014 | B2 |
8784406 | Rathjen | Jul 2014 | B2 |
8870934 | Muller et al. | Oct 2014 | B2 |
8882757 | Muller et al. | Nov 2014 | B2 |
8887734 | Bueler et al. | Nov 2014 | B2 |
8936591 | Mrochen et al. | Jan 2015 | B2 |
8945101 | Herekar et al. | Feb 2015 | B2 |
8992023 | Perez et al. | Mar 2015 | B2 |
8992516 | Muller | Mar 2015 | B2 |
9006182 | Soltz et al. | Apr 2015 | B2 |
9020580 | Friedman et al. | Apr 2015 | B2 |
9044308 | Muller et al. | Jun 2015 | B2 |
9125735 | de Juan, Jr et al. | Sep 2015 | B2 |
9125856 | Paik et al. | Sep 2015 | B1 |
9192594 | Troisi et al. | Nov 2015 | B2 |
9289396 | Devore et al. | Mar 2016 | B2 |
9411938 | Rathjen | Aug 2016 | B2 |
9439908 | Foschini et al. | Sep 2016 | B2 |
9445870 | Chuck et al. | Sep 2016 | B2 |
9452172 | Scherz et al. | Sep 2016 | B2 |
9463178 | Smith | Oct 2016 | B2 |
9486284 | Depfenhart et al. | Nov 2016 | B2 |
9498114 | Friedman et al. | Nov 2016 | B2 |
9498122 | Friedman et al. | Nov 2016 | B2 |
9498642 | Muller et al. | Nov 2016 | B2 |
9504607 | Russmann | Nov 2016 | B2 |
9555111 | Rubinfeld et al. | Jan 2017 | B2 |
9566301 | Rubinfeld et al. | Feb 2017 | B2 |
9622911 | Rubinfeld et al. | Apr 2017 | B2 |
9664926 | Mitsui | May 2017 | B2 |
9700456 | Foschini et al. | Jul 2017 | B2 |
9707126 | Friedman et al. | Jul 2017 | B2 |
9724233 | Blumenkranz et al. | Aug 2017 | B2 |
9737438 | Rathjen | Aug 2017 | B2 |
9788996 | Roy et al. | Oct 2017 | B2 |
9802059 | Saks | Oct 2017 | B2 |
9814567 | Peyman | Nov 2017 | B2 |
9855168 | Wellhoefer | Jan 2018 | B2 |
9861526 | Cooper et al. | Jan 2018 | B1 |
9883970 | Lopath et al. | Feb 2018 | B2 |
9889041 | Iseli | Feb 2018 | B2 |
9907698 | Cooper et al. | Mar 2018 | B2 |
9907977 | Skerl | Mar 2018 | B2 |
10010449 | Lopath | Jul 2018 | B2 |
10028657 | Friedman | Jul 2018 | B2 |
10064753 | Daxer | Sep 2018 | B2 |
10092594 | Rubinfeld et al. | Oct 2018 | B2 |
10098782 | Depfenhart | Oct 2018 | B2 |
10105350 | Paik et al. | Oct 2018 | B2 |
10130511 | Dantus | Nov 2018 | B2 |
10137239 | Friedman et al. | Nov 2018 | B2 |
10141075 | Dupps, Jr. | Nov 2018 | B2 |
10166314 | Phopase et al. | Jan 2019 | B2 |
10182941 | Hafezi et al. | Jan 2019 | B2 |
10195081 | Peyman | Feb 2019 | B1 |
10219944 | Tedford et al. | Mar 2019 | B2 |
10231968 | Hardten et al. | Mar 2019 | B2 |
10258506 | Depfenhart | Apr 2019 | B2 |
10258809 | Friedman et al. | Apr 2019 | B2 |
10285857 | Rubinfeld et al. | May 2019 | B2 |
10335316 | Bor et al. | Jul 2019 | B2 |
10342697 | Friedman et al. | Jul 2019 | B2 |
10345590 | Samec et al. | Jul 2019 | B2 |
10350111 | Friedman et al. | Jul 2019 | B2 |
10363170 | Skerl et al. | Jul 2019 | B2 |
10383721 | Marcos Celestino et al. | Aug 2019 | B2 |
10426659 | Myung et al. | Oct 2019 | B2 |
10426663 | Iseli | Oct 2019 | B2 |
10449090 | Muller | Oct 2019 | B2 |
10463610 | Williams et al. | Nov 2019 | B2 |
10463735 | Xie et al. | Nov 2019 | B2 |
10569098 | Depfenhart et al. | Feb 2020 | B2 |
10575986 | Rubinfeld | Mar 2020 | B2 |
10729716 | Rubinfeld et al. | Aug 2020 | B2 |
11033429 | Rubinfeld et al. | Jun 2021 | B2 |
20010016731 | DeVore et al. | Aug 2001 | A1 |
20010022063 | Korteweg | Sep 2001 | A1 |
20020006394 | Redmond et al. | Jan 2002 | A1 |
20020013577 | Frey et al. | Jan 2002 | A1 |
20020022606 | Kochevar et al. | Feb 2002 | A1 |
20020040218 | Fujieda | Apr 2002 | A1 |
20020100990 | Platt | Aug 2002 | A1 |
20020118338 | Kohayakawa | Aug 2002 | A1 |
20030083649 | Margaron et al. | May 2003 | A1 |
20030105521 | Perez | Jun 2003 | A1 |
20030175259 | Karageozian et al. | Sep 2003 | A1 |
20030203839 | Kruzel et al. | Oct 2003 | A1 |
20030208190 | Roberts et al. | Nov 2003 | A1 |
20030225041 | Nolan | Dec 2003 | A1 |
20030232287 | Bango | Dec 2003 | A1 |
20040137068 | Bhushan | Jul 2004 | A1 |
20050070942 | Perez | Mar 2005 | A1 |
20050090877 | Harth et al. | Apr 2005 | A1 |
20050124982 | Perez | Jun 2005 | A1 |
20050149006 | Peyman | Jul 2005 | A1 |
20050152993 | De Oliveira | Jul 2005 | A1 |
20050241653 | Van Heugten et al. | Nov 2005 | A1 |
20050271590 | Schwartz et al. | Dec 2005 | A1 |
20050283234 | Zhou et al. | Dec 2005 | A1 |
20060073172 | Schneider et al. | Apr 2006 | A1 |
20060074487 | Gilg | Apr 2006 | A1 |
20060084951 | Heacock et al. | Apr 2006 | A1 |
20060106371 | Muhlhoff et al. | May 2006 | A1 |
20060134170 | Griffith et al. | Jun 2006 | A1 |
20060166879 | Bhushan et al. | Jul 2006 | A1 |
20060172972 | Bhushan et al. | Aug 2006 | A1 |
20060177430 | Bhushan et al. | Aug 2006 | A1 |
20060206173 | Gertner et al. | Sep 2006 | A1 |
20060235513 | Price | Oct 2006 | A1 |
20060254602 | Myer | Nov 2006 | A1 |
20060268231 | Gil et al. | Nov 2006 | A1 |
20060275278 | Choy et al. | Dec 2006 | A1 |
20060287662 | Berry et al. | Dec 2006 | A1 |
20070021806 | Mercier et al. | Jan 2007 | A1 |
20070088415 | Peyman | Apr 2007 | A1 |
20070128174 | Kleinsek et al. | Jun 2007 | A1 |
20070129286 | Zhang | Jun 2007 | A1 |
20070135805 | Peyman | Jun 2007 | A1 |
20070142828 | Peyman | Jun 2007 | A1 |
20070156077 | Pfister | Jul 2007 | A1 |
20070167935 | Serdarevic | Jul 2007 | A1 |
20070203478 | Herekar | Aug 2007 | A1 |
20070207116 | Brown | Sep 2007 | A1 |
20070225778 | Heacock et al. | Sep 2007 | A1 |
20080009901 | Redmond et al. | Jan 2008 | A1 |
20080015660 | Herekar | Jan 2008 | A1 |
20080039769 | Peyman | Feb 2008 | A1 |
20080057023 | Chynn et al. | Mar 2008 | A1 |
20080089923 | Burkstrand et al. | Apr 2008 | A1 |
20080097174 | Maynard et al. | Apr 2008 | A1 |
20080114283 | Mattson et al. | May 2008 | A1 |
20080139671 | Herekar | Jun 2008 | A1 |
20080161780 | Serdarevic | Jul 2008 | A1 |
20080208177 | Mrochen et al. | Aug 2008 | A1 |
20080246920 | Buczek et al. | Oct 2008 | A1 |
20080269119 | Griffith et al. | Oct 2008 | A1 |
20080269730 | Dotson | Oct 2008 | A1 |
20080288063 | Price, Jr. | Nov 2008 | A1 |
20090024117 | Muller | Jan 2009 | A1 |
20090069798 | Muller et al. | Mar 2009 | A1 |
20090099557 | Sedarevic | Apr 2009 | A1 |
20090105127 | Thompson et al. | Apr 2009 | A1 |
20090149842 | Muller et al. | Jun 2009 | A1 |
20090149923 | Herekar | Jun 2009 | A1 |
20090171305 | El Hage | Jul 2009 | A1 |
20090187178 | Muller et al. | Jul 2009 | A1 |
20090187184 | Muller | Jul 2009 | A1 |
20090192437 | Soltz et al. | Jul 2009 | A1 |
20090209954 | Muller et al. | Aug 2009 | A1 |
20090275923 | Shimizu et al. | Nov 2009 | A1 |
20090275929 | Zickler | Nov 2009 | A1 |
20100057059 | Makino | Mar 2010 | A1 |
20100057060 | Herekar | Mar 2010 | A1 |
20100069894 | Mrochen et al. | Mar 2010 | A1 |
20100082018 | Panthakey et al. | Apr 2010 | A1 |
20100087920 | Marmo | Apr 2010 | A1 |
20100094197 | Marshall et al. | Apr 2010 | A1 |
20100094280 | Muller | Apr 2010 | A1 |
20100114109 | Peyman | May 2010 | A1 |
20100173019 | Paik et al. | Jul 2010 | A1 |
20100179622 | Wagenaar Cacciola et al. | Jul 2010 | A1 |
20100185192 | Muller et al. | Jul 2010 | A1 |
20100189817 | Krueger et al. | Jul 2010 | A1 |
20100210996 | Peyman | Aug 2010 | A1 |
20100256705 | Muller et al. | Oct 2010 | A1 |
20100286156 | Pinelli | Nov 2010 | A1 |
20100312198 | Guidi | Dec 2010 | A1 |
20100318017 | Lewis et al. | Dec 2010 | A1 |
20110060129 | Akashi et al. | Mar 2011 | A1 |
20110060267 | DeWoolfson et al. | Mar 2011 | A1 |
20110081323 | Kleinsek et al. | Apr 2011 | A1 |
20110086802 | Dewoolfson et al. | Apr 2011 | A1 |
20110098790 | Daxer | Apr 2011 | A1 |
20110118654 | Muller et al. | May 2011 | A1 |
20110125187 | Soltz et al. | May 2011 | A1 |
20110149247 | Artsyukhovich | Jun 2011 | A1 |
20110152219 | Stagni | Jun 2011 | A1 |
20110160710 | Frey et al. | Jun 2011 | A1 |
20110190742 | Anisimov | Aug 2011 | A1 |
20110237999 | Muller et al. | Sep 2011 | A1 |
20110264082 | Mrochen et al. | Oct 2011 | A1 |
20110280763 | Trokel et al. | Nov 2011 | A1 |
20110282333 | Herekar et al. | Nov 2011 | A1 |
20110288466 | Muller et al. | Nov 2011 | A1 |
20110301524 | Bueler et al. | Dec 2011 | A1 |
20110306956 | Islam | Dec 2011 | A1 |
20120059439 | Yoon | Mar 2012 | A1 |
20120065572 | Lewis et al. | Mar 2012 | A1 |
20120083772 | Rubinfeld et al. | Apr 2012 | A1 |
20120087970 | Newman | Apr 2012 | A1 |
20120095455 | Rodmond et al. | Apr 2012 | A1 |
20120121567 | Troisi et al. | May 2012 | A1 |
20120148543 | Connon | Jun 2012 | A1 |
20120150160 | Vogler et al. | Jun 2012 | A1 |
20120203161 | Herekar | Aug 2012 | A1 |
20120215155 | Muller et al. | Aug 2012 | A1 |
20120238938 | Herekar et al. | Sep 2012 | A1 |
20120283531 | Maynard et al. | Nov 2012 | A1 |
20120283621 | Muller | Nov 2012 | A1 |
20120289886 | Muller et al. | Nov 2012 | A1 |
20120303008 | Muller et al. | Nov 2012 | A1 |
20120310083 | Friedman et al. | Dec 2012 | A1 |
20120310141 | Kornfield et al. | Dec 2012 | A1 |
20130060187 | Friedman et al. | Mar 2013 | A1 |
20130079759 | Dotson et al. | Mar 2013 | A1 |
20130085370 | Friedman et al. | Apr 2013 | A1 |
20130110091 | Berry | May 2013 | A1 |
20130131664 | Muller et al. | May 2013 | A1 |
20130158342 | Chan et al. | Jun 2013 | A1 |
20130245536 | Friedman et al. | Sep 2013 | A1 |
20130267528 | Pinelli | Oct 2013 | A1 |
20130331768 | Nichamin | Dec 2013 | A1 |
20140024997 | Muller et al. | Jan 2014 | A1 |
20140031845 | Rynerson | Jan 2014 | A1 |
20140142200 | Duan et al. | May 2014 | A1 |
20140155800 | de Juan, Jr et al. | Jun 2014 | A1 |
20140171490 | Gross et al. | Jun 2014 | A1 |
20140276361 | Herekar et al. | Sep 2014 | A1 |
20140320819 | Muller et al. | Oct 2014 | A1 |
20140343480 | Kamaev et al. | Nov 2014 | A1 |
20140368792 | Friedman et al. | Dec 2014 | A1 |
20140368793 | Friedman et al. | Dec 2014 | A1 |
20150032686 | Kuchoor | Jan 2015 | A1 |
20150088231 | Rubinfeld et al. | Mar 2015 | A1 |
20150126921 | Rubinfeld et al. | May 2015 | A1 |
20150174161 | Rubinfeld et al. | Jun 2015 | A1 |
20150182659 | Fabian | Jul 2015 | A1 |
20150305933 | Zhou | Oct 2015 | A1 |
20150359668 | Kornfield et al. | Dec 2015 | A1 |
20160038760 | Hamrah et al. | Feb 2016 | A1 |
20160151202 | Scarcelli et al. | Jun 2016 | A1 |
20160175442 | Kamaev et al. | Jun 2016 | A1 |
20160236006 | Donitzky et al. | Aug 2016 | A1 |
20160303284 | Borde et al. | Oct 2016 | A1 |
20160325499 | Muller | Nov 2016 | A1 |
20170021021 | Kamaev et al. | Jan 2017 | A1 |
20170043015 | Alageel et al. | Feb 2017 | A1 |
20170156926 | Friedman et al. | Jun 2017 | A1 |
20170246471 | Lopath | Aug 2017 | A1 |
20170367879 | Lopath et al. | Dec 2017 | A1 |
20180028834 | Saks | Feb 2018 | A1 |
20180050088 | Green et al. | Feb 2018 | A1 |
20180078677 | Cho et al. | Mar 2018 | A1 |
20180098884 | Ko et al. | Apr 2018 | A1 |
20180177587 | Anderson et al. | Jun 2018 | A1 |
20180193188 | Vukelic et al. | Jul 2018 | A1 |
20180206719 | Adler et al. | Jul 2018 | A1 |
20180214552 | Sui et al. | Aug 2018 | A1 |
20180228599 | Elisseeff et al. | Aug 2018 | A1 |
20180236261 | Smith et al. | Aug 2018 | A1 |
20180243082 | Zheleznyak et al. | Aug 2018 | A1 |
20180353629 | Neister et al. | Dec 2018 | A9 |
20190008683 | Mitsui | Jan 2019 | A1 |
20190022220 | Goldberg et al. | Jan 2019 | A1 |
20190083529 | Ambati et al. | Mar 2019 | A1 |
20190159934 | Bischoff et al. | May 2019 | A1 |
20190192840 | Friedman et al. | Jun 2019 | A1 |
20190201710 | Shiuey | Jul 2019 | A1 |
20190255226 | Jessop et al. | Aug 2019 | A1 |
20190314548 | Shiuey | Oct 2019 | A1 |
Number | Date | Country |
---|---|---|
2319087 | Aug 1999 | CA |
2418306 | Jan 2002 | CA |
2473703 | Jul 2003 | CA |
2511217 | Jul 2004 | CA |
2515720 | Sep 2004 | CA |
2566961 | Dec 2005 | CA |
2576308 | Feb 2006 | CA |
2577025 | Feb 2006 | CA |
2700884 | Feb 2009 | CA |
10323422 | Apr 2004 | DE |
102013004482 | Sep 2014 | DE |
102014017197 | Jun 2016 | DE |
102016006083 | Nov 2017 | DE |
102017104024 | Aug 2018 | DE |
330389 | May 1997 | EP |
590772 | Apr 1998 | EP |
1051655 | Sep 2005 | EP |
1561440 | Apr 2009 | EP |
2077900 | Jul 2009 | EP |
1790383 | Jul 2010 | EP |
2253321 | Nov 2010 | EP |
2323642 | Feb 2014 | EP |
2407132 | Apr 2014 | EP |
2236109 | Oct 2014 | EP |
2802302 | Nov 2014 | EP |
2663281 | Aug 2016 | EP |
2797492 | Dec 2017 | EP |
3288588 | Aug 2018 | EP |
3122296 | Oct 2018 | EP |
3407920 | Dec 2018 | EP |
3426219 | Jan 2019 | EP |
3458000 | Mar 2019 | EP |
2712311 | Jun 2019 | EP |
3053553 | Sep 2019 | EP |
3003375 | Nov 2019 | EP |
54101440 | Aug 1979 | JP |
1803110 | Mar 1993 | RU |
200063079 | Oct 2000 | WO |
0111716 | Feb 2001 | WO |
2001082933 | Nov 2001 | WO |
03061518 | Jul 2003 | WO |
03068247 | Aug 2003 | WO |
2004024035 | Mar 2004 | WO |
2005117987 | Dec 2005 | WO |
2007011874 | Jan 2007 | WO |
2007011875 | Jan 2007 | WO |
2007020673 | Feb 2007 | WO |
2007026382 | Mar 2007 | WO |
2007035843 | Mar 2007 | WO |
2007082127 | Jul 2007 | WO |
2008005059 | Jan 2008 | WO |
2008055118 | May 2008 | WO |
2009146151 | Dec 2009 | WO |
2010011119 | Jan 2010 | WO |
2010019072 | Feb 2010 | WO |
2009001396 | Mar 2010 | WO |
2010023705 | Mar 2010 | WO |
2010093908 | Aug 2010 | WO |
2011011202 | Jan 2011 | WO |
2011019940 | Feb 2011 | WO |
2011041437 | Apr 2011 | WO |
2011050164 | Apr 2011 | WO |
2011050164 | Apr 2011 | WO |
2011056477 | May 2011 | WO |
2011109712 | Sep 2011 | WO |
2011152861 | Dec 2011 | WO |
2012035403 | Mar 2012 | WO |
2012047307 | Apr 2012 | WO |
2013148895 | Oct 2013 | WO |
2013148896 | Oct 2013 | WO |
2013158611 | Oct 2013 | WO |
2014066636 | May 2014 | WO |
2014071408 | May 2014 | WO |
2014089548 | Jun 2014 | WO |
2014145666 | Sep 2014 | WO |
2014174544 | Oct 2014 | WO |
2016178586 | Nov 2016 | WO |
2016195152 | Dec 2016 | WO |
2017184717 | Oct 2017 | WO |
2018144477 | Aug 2018 | WO |
2018156593 | Aug 2018 | WO |
2019149802 | Aug 2018 | WO |
2018213795 | Nov 2018 | WO |
2019173759 | Sep 2019 | WO |
Entry |
---|
Communication Pursuant to Article 94(3) EPC issued in EP13767439.6 dated Dec. 9, 2019. |
Third Party Observation for European application No. 13767439.6 submitted to the European Patent Office on Apr. 13, 2019 in 2 pages. |
Baranowski, “Ophthlamic Drug Dosage Forms: Characterisation and Research Methods,” The Scientific World Journal, vol. 2014, pp. 1-14 (2014). |
Kim et al. (Wiley Periodicals, Wiley InterScience, Jun. 2009, pp. 390-400, 2009. |
Xie et al., Progress in Polymer Science, 2019, vol. 95, pp. 32-64, 2019. |
Arbelaex et al., Oman Journal of Ophthamalogy, 2009, vol. 2, pp. 33-38, 2009. |
Baldursdottir et al. (Biomacromolecules, 2003, vol. 4, pp. 429-436) (Year: 2003). |
El-Raggal (Riboflavin-Ultraviolet A Corneal Cross linking for Keratoconus, Middle East Afr. J. Ophthalmol. Oct.-Dec. 2009; 16(4):256-259). |
Bessonova, et al., “A study of the stability of eye drops containing riboflavine (Russian).” XP002719481. Database accession No. EMB-1978057912. Abstract Elseview Science Publishers, Amsterdam, NL 1977. |
Elstner, et al. “Uptake and biochemical activity of potassium iodide in isolated rabbit eyes.” XP008167001. Phtlalmologica 191(2):122-126 (1985). English Abstract. |
Koltun, et al. “improving the production technology of vitamin-containing eye drops to ensure their microbiological purity.” CP00271948, Database accession No. PREV199497454025. Abstract Biosciences information service, Philadelphia, PA, 1993. |
Rieger, “Anti-oxidtaive capacity of various articifial tear prepartions.” XPO003014992, Graefe's Archive for Clinical Experimental Ophthalmology. 239:222-226 (2001). |
Schmut, et al. “Iodide protection from UVB irradiation-induced degradation of hyaluronate and against UVB- damaage of human conjunctival fibroblasts.” Graefe's Arch Clin Exp Ophthalmol 242:279-283 2004. |
Shimmura, et al. “Subthershold UV radiation-induced peroxide formation in cultured coreal epithelial cells: the protective effects of lactoferrin” Exp. Eye Res. 63: 519-526 1996. |
Ishimitsu “The photochemical decomposition and hydroxylation of phenylalanine in the presence of riboflavin” Chem. Pharm. Bul. 33(4): 1552-1556 1985. |
Zhang, et al. “Clinical effect of traditional Chinese herb combined with sodium iodide in treating corneal opacity.” XP-002719483, International Journal of Ophthalmology, 7: 217-219, 2007. |
Extended European Search Report dated Feb. 10, 2014 for related EP Patent Application No. 11831060 in 15 pages. |
Cho et al. “Reactive Oxygen Species-Induced Apoptosis and Necrosis in Bovine Corneal Endothelial Cells.” Investigative Ophthalmology & Visual Science. 40(5):911-919, Apr. 1999. |
Fujimori. “Cross-linking and fluorescence changes of collagen by glycation and oxidation.” Biochimica et Biophysica Acta. 998:105-110, 1989. |
Hull et al. “Hydrogen Peroxide-Mediated Corneal Endothelial Damage.” Investigative Ophthalmology & Visual Science. 25:1246-1253, 1984. |
Iseli et al. “Efficacy and Safety of Blue-light Scleral Cross-linking.” International Congress of Corneal Cross-Linking, Dec. 7-8, 2007; Zurich, Switzerland. pp. S752-S755. |
Khadem et al. “Photodynamic Biologic Tissue Glue.” Cornea. 13(5):406-410, 1994. |
Kohlhaas et al. “Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light.” J Cataract Refract Surg. 32:279-283, Feb. 2006. |
Krueger et al. “Rapid vs Standard Collagen CXL with Equivalent Energy Dosing.” Third International Congress of Corneal Cross-linking. Dec. 7-8, 2007; Zurich, Switzerland, in 25 pages. |
Sato et al. “The Primary Cytotoxicity in Ultraviolet-A-Irradiated Riboflavin Solution is Derived from Hydrogen Peroxide.” The Society for Investigative Dermatology, Inc. 105(4):608-612, Oct. 1995. |
Seiler et al. “Corneal Cross-Linking-Induced Stromal Demarcation Line.” Clinical Science. 25(9):1057-1059, Oct. 2006. |
Spoerl et al. “Increased resistance of cross-linked cornea against enzymatic digestion.” Current Eye Research. 29(1):35-40, 2004. |
Spoerl et al. “Induction of Cross-links in Corneal Tissue.” Exp. Eye Res. 66:97-103, 1998. |
Spoerl et al. “Safety of UVA-Riboflavin Cross-Linking of the Cornea.” Cornea. 26(4):385-389, May 2007. |
Spoerl et al. “Thermo-mechanical Behavior of Collagen-Cross-Linked Porcine Cornea.” Ophthalmologica. 218:136-140, 2004. |
Wollensak et al. “Collagen Fiber Diameter in the Rabbit Cornea After Collagen Cross-linking by Riboflavin/UVA.” Cornea. 23(5):503-507, Jul. 2004. |
Wollensak et al. “Corneal Endothelial Cytotoxicity of Riboflavin/UVA Treatment in vitro.” Ophthalmic Res. 35:324-328, 2003. |
Wollensak et al. “Endothelial cell damage after riboflavin-ultraviolet-A treatment in the rabbit.” J Cataract Refract Surg. 29:1786-1790, 2003. |
Wollensak et al. “Keratocyte Apoptosis After Corneal Collagen Cross-linking Using Riboflavin/UVA Treatment.” Cornea. 23(1):43-49, Jan. 2004. |
Wollensak et al. “Keratocyte cytotoxicity of riboflavin/UVA treatment in vitro.” Eye. 2004, in 5 pages. |
Wollensak et al. “Long-term biomechanical properties of rabbis cornea after photo-dynamic collagen cross-linking.” Acta Ophthalmologica. 87:48-51, 2009. |
Wollensak et al. “Riboflavin/Ultraviolet-A-induced Collagen Cross-linking for the Treatment of Keratoconus.” Am J Ophthalmol. 135:620-627, 2003. |
Wollensak et al. “Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking.” J Cataract Refract Surg. 29:1780-1785, 2003. |
Wollensak et al. “Wound Healing in the Rabbit Cornea After Corneal Collagen Cross-Linking With Riboflavin and UVA.” Cornea. 26:600-605, 2007. |
International Search Report and Written Opinion for related international application No. PCTUS2013/034185, dated Jul. 11, 2013, in 10 pages. |
International Search Report and Written Opinion for related international application No. PCTUS2013033923, dated Jul. 12, 2013, in 11 pages. |
Epstein.“Refraktive Chirurgie.” Therapeutische Umschau. Revue Therapeutique. 66(3):207-210 (Mar. 2009). English abstract. |
Chuo et al. “Modern Corneal and Refractive Procedures.” Expert Review of Ophthalmology. 6(2):247-266 (Apr. 2011). |
Kullman. “Alternative Applications of the Femtosecond Laser in Ophthalmology.” Seminars in Ophthalmology. 25(5-6):256-264 (Nov. 2010). |
Kohnen et al. “Bewertung und Qualitätssicherung refraktiv-chirurgischer Eingriffe durch die DOG und den BVA (Evaluation and quality assurance of refractive surgery by the German Ophthalmological Society and the Professional Association of German Ophthalmologists).” Ophthalmologie. 108(9):869-882 (Sep. 2011). Available only in German. |
Kato et al. “Topography-Guided Conductive Keratoplasty: Treatment for Advanced Keratoconus.” American Journal of Ophthalmology. 150(4):481-489 (Oct. 2010). |
Oduntan et al. “A review of the role of oxidative stress in the pathogenesis of eye diseases.” S Afr Optom. 70(4):191-199 (2011). |
Gilgun-Sherki et al. Oxidative stress induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier, Neuropharmacology 40: 959-975, 2001. |
Bickers et al. “Oxidative Stress in the Pathogenesis of Skin Disease.” The Society for Investigative Dermatology. pp. 2565-2575, 2006. |
Sukkar et al. “Oxidative stress and nutritional prevention in autoimmune rheumatic diseases.” Autoimmunity Reviews. 3:199-206 (2004). |
Uttara et al. “Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options.” Current Neuropharmacology. 7:65-74 (2009). |
Wells et al. “Oxidative Stress in Developmental Origins of Disease: Teratogenesis, Neurodevelopmental Deficits, and Cancer.” Toxicological Sciences. 108(1):4-18 (2009). |
EMX Industries, Inc .; ColoMax HEX color sensors; Mar. 2010. |
International Search Report and Written Opinion for related PCT/US2014/024770 dated Aug. 6, 2014 in 17 pages. |
Wollensak et al., “Cross-linking of scleral collagen in the rabbit using riboflavin and UVA”, ACTA Ophthalmologica Scandinavica, 2005, vol. 83, pp. 477-482. |
International Search Report and Written Opinion for related international application No. PCT/US2013/034467 dated Jul. 26, 2013 in 12 pages. |
Agbor, et al. “Effect of Iodine Supplementation on Antioxidant Status of Normal and Alloxan Monohydrate in Toxicated Rats”, International Journal of Pharmacology, 7 (6): pp. 726-731, 2011, Asian Network for Scientific Information. |
Rieger, et al. “The Effect of lodide lontophoresis on the Antioxidative Capacity of the Tear Fluid” Graefe's Archive for Clinical Experimental Ophthalmology. 248:1639-1646 (2010). |
Supplementary European Search Report for EP 13767439.6 dated Sep. 15, 2015 in 6 pages. |
Horwath-Winter J, et al: “Iodide iontophoresis as a treatment for dry eye syndrome”, The British Journal of Ophthalmology, Jan. 2005, pp. 40-44, vol. 89, No. 1. |
Singh et al: “Clinical Evaluation of Sodium Iodide in the Treatment of Various Types of Cataracts”, Journal of the Indian Medical Association, 1983, pp. 119-121, vol. 81, No. 7-8. |
Winkler et al: “Effect of Iodide on Total Antioxidant Status of Human Serum”, Cell Biochemistry and Function, Jun. 2000, pp. 143-146, vol. 18, No. 2. |
Partial supplementary European Search Report for EP 13768403.1 dated Oct. 23, 2015 in 10 pages. |
Ilens Ophthalmic Solution, http://naikutty.in/medicine-list-i/article/86937-ilens-solution, Date unknown but available prior to the date of this application, access date Dec. 22, 2015. |
J. Wernli, S. Schumacher, E. Spoerl, and M. Mrochen, “The efficacy of corneal cross-linking shows a sudden decrease with very high intensity UV light and short treatment time,” Investigative Ophthalmology and Visual Science, vol. 54, No. 2, pp. 1176-1180, Feb. 2013. |
R. R. Krueger, E Spoerl, and S. Herekar, “Rapid vs standard collagen CXL with equivalent energy dosing,” in Proceedings of the 3rd International Congress of Corneal Collagen Cross-Linking, Zurich, Switzerland, Dec. 2007. |
Pavel Kamaev, et al,. “Photochemical kinetics of corneal cross-linking with Riboflucin”, Investigative Ophthalmology and Visual Science, Apr. 2012, vol. 53, No. 4, 2360-2367. |
Extended European Search Report dated Oct. 19, 2016 for related EP Patent Application No. 14775693.6 in 8 pages. |
International Search Report and written opinion dated Jan. 17, 2012 for PCT/US2011/033873. |
Olson, “Control lamp flora in developed caves” Heldreth-Werker V. & Werker J.C. Cave Conservation and Restoration, Huntsville: National Speleolgical Society: 343-348. |
Baert, et al “Medical Radiology: Diagnostic Imaging, Radiological Imaging of the Ureter, copyright 2003, Springer” (Joffre, et all.) DOI https://doi.org/10.1007/978-3-642-55831-3. |
Abraxis (Iodopen MSDS, Revision date of Jun. 13, 2006). |
International Preliminary Report on patentability for PCT/US2013/034185, dated Oct. 1, 2014, in 7 pages. |
Harvey, et al. “Formulation and stability of a novel artificial human sweat under conditions of storage and use” Toxicology in Vitro, 2010, vol. 24, pp. 1790-1796. |
International Preliminary Report on patentability for PCT/US2013/034467, dated Oct. 1, 2014, in 6 pages. |
Extended European Search Report issued in EP18196714.2 dated Jan. 30, 2019 in 8 pages. |
Rose, R. C. et al.: “Ocular oxidants and antioxidant protection”, Experimental Biology and Medicine, vol. 217, No. 4, 1998, pp. 397-407. |
Ibusuki et al.: “Photochemically Cross-Linked Collagen Gels as Three-Dimensional Scaffolds for Tissue Engineering”, Tissue Engineering, vol. 13, No. 8, Aug. 14, 2007, pp. 1995-2001. |
Third Party Observation for European application No. 13767439.6 submitted to the European Patent Office on Nov. 30, 2018, in 2 pages. |
Hafezi, Cross-linking of corneal collagen with UVA and riboflavin for the treatment of corneal disease,2009, Iranian Journal of Ophthalmology, col. 21, No. 2, pp. 3-12/. |
Letko, et al. UVA-light and riboflavin-mediated corneal collagen cross-linking, 2011 International ophthalmology climics. Www.intrnat-ophthalmology.com, pp. 1-14. |
Beijin Yasi Technology and Development Co., Ltd Eye sponge product information, Jul. 29, 2011. |
International Search Report and Written Opinion issued in PCT/US2013/034187 dated Jul. 22, 2013 in 21 pages. |
Extended European Search Report for European application No. 18182071.3 dated Oct. 2, 2018 in 6 pages. |
Extended European Search Report for European application No. 15793441.5 dated Jan. 2, 2017. |
International Search Report and Written Opinion for PCT/US2015/029011 dated Aug. 3, 2015 in 14 pages. |
Iseli et al., Laboratory Measurement of the Absorption Coefficient of Riboflavin for Ultraviolet Light (365 nm), Journal of Refractive Surgery, 2011, 27(3):195-201, Jun. 4, 2010, 3 pages. |
Number | Date | Country | |
---|---|---|---|
20200146886 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
61617339 | Mar 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14275192 | May 2014 | US |
Child | 16738735 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2013/034187 | Mar 2013 | US |
Child | 14275192 | US |